Review Article

You have full text access to this OnlineOpen article

Estimating the optimal external-beam radiotherapy utilization rate for genitourinary malignancies

  1. Geoff Delaney M.B.B.S., M.D.†,*,
  2. Susannah Jacob M.B.B.S., M.D.,
  3. Michael Barton M.B.B.S.

Article first published online: 20 DEC 2004

DOI: 10.1002/cncr.20789

Issue

Cancer

Cancer

Volume 103, Issue 3, pages 462–473, 1 February 2005

Additional Information

How to Cite

Delaney, G., Jacob, S. and Barton, M. (2005), Estimating the optimal external-beam radiotherapy utilization rate for genitourinary malignancies. Cancer, 103: 462–473. doi: 10.1002/cncr.20789

Author Information

  1. Collaboration for Cancer Outcomes Research and Evaluation, Liverpool Hospital, Sydney, Australia

  1. †

    Fax: (011) 61-2-9828-5299

*Collaboration for Cancer Outcomes Research and Evaluation, Liverpool Hospital, Locked Bag 7103, Liverpool, New South Wales, 1871, Australia

Publication History

  1. Issue published online: 20 JAN 2005
  2. Article first published online: 20 DEC 2004
  3. Manuscript Accepted: 7 OCT 2004
  4. Manuscript Revised: 7 SEP 2004
  5. Manuscript Received: 18 MAY 2004

Funded by

  • Australian Commonwealth Department of Health and Ageing

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (298K)

REFERENCES

  • 1
    Delaney G, Barton B, Jacob S. Estimation of an optimal radiotherapy utilization rate for breast cancer: a review of the evidence. Cancer. 2003; 98: 1977–1986.
    Direct Link:
  • 2
    Foroudi F, Tyldesley S, Walker H, Mackillop WJ. An evidence-based estimate of appropriate radiotherapy utilization rate for breast cancer. Int J Radiat Oncol Biol Phys. 2002; 53: 1240–1253.
  • 3
    Delaney G, Barton M, Jacob S, Jalaludin B. A model for decision making for the use of radiotherapy in lung cancer. Lancet Oncol. 2003; 4: 120–128.
  • 4
    Tyldesley S, Boyd C, Shulze K, Walker H, Mackillop WJ. Estimating the need for radiotherapy for lung cancer: an evidence-based, epidemiologic approach. Int J Radiat Oncol Biol Phys. 2001; 49: 973–985.
  • 5
    Foroudi F, Tyldesley S, Barbera L, Huang J, Mackillop WJ. An evidence-based estimate of the appropriate radiotherapy utilization rate for colorectal cancer. Int J Radiat Oncol Biol Phys. 2003; 56: 1295–1307.
  • 6
    Delaney G, Barton M, Jacob S. Estimation of an optimal radiotherapy utilization rate for melanoma. A review of the evidence. Cancer. 2004; 100: 1293–1301.
    Direct Link:
  • 7
    Foroudi F, Tyldesley S, Barbera L, Huang J, Mackillop WJ. Evidence-based estimate of appropriate radiotherapy utilization rate for prostate cancer. Int J Radiat Oncol Biol Phys. 2003; 55: 51–63.
  • 8
    National Cancer Institute. PDQ cancer information summaries: treatment of renal cell cancer. Available from URL: www.nci.nih.gov [accessed August 29, 2002].
  • 9
    BC Cancer Agency. Cancer management guidelines: renal cancer. Available from URL: http://www.bccancer.bc.ca [accessed August 29, 2002].
  • 10
    National Comprehensive Cancer Network. Clinical practice guidelines in oncology—v.1.2003—kidney cancer. Available from URL: www.nccn.org [accessed August 5, 2003].
  • 11
    National Cancer Institute. PDQ cancer information summaries: treatment of bladder cancer. Available from URL: www.nci.nih.gov [accessed August 29, 2002].
  • 12
    BC Cancer Agency. Cancer management guidelines: bladder cancer. Available from URL: http://www.bccancer.bc.ca [accessed August 29, 2002].
  • 13
    Morey SM. American Urological Association issues guidelines on the management of bladder cancer. Am Fam Phys. 2000; 61: 3734–3736.
  • 14
    National Comprehensive Cancer Network. Practice guidelines in oncology—v.1.2002—bladder cancer. Available from URL: www.nccn.org [accessed October 31, 2002].
  • 15
    National Cancer Institute. PDQ cancer information summaries: treatment of testicular cancer. Available from URL: www.nci.nih.gov [accessed August 29, 2002].
  • 16
    BC Cancer Agency. Cancer management guidelines: management of testicular cancer. Available from URL: http://www.bccancer.bc.ca [accessed August 28, 2002].
  • 17
    Royal College of Radiologists COIN (Clinical Oncology Information Network) Scottish Intercollegiate Guidelines Network. Guidelines on the management of adult testicular germ cell tumours. Available from URL: http://www.rcr.ac.uk/testicular.htm [accessed August 29, 2002].
  • 18
    National Comprehensive Cancer Network. NCCN practice guidelines for testicular cancer. Oncology. 1998; 12: 417–462.
  • 19
    Laguna MP, Pizzocaro G, Klepp O, for the EAU Working Group on Oncological Urology. EAU guidelines on testicular cancer. Eur Urol. 2001; 40: 102–110.
  • 20
    Krege S, Souchon R, Schmoll HJ, for the German Testicular Cancer Study Group. Interdisciplinary consensus on diagnosis and treatment of testicular germ cell tumors: result of an update conference on evidence-based medicine. Eur Urol. 2001; 40: 372–391.
  • 21
    National Cancer Institute. PDQ cancer information summaries: treatment of prostate cancer. Available from URL: www.nci.nih.gov [accessed October 16, 2001].
  • 22
    National Comprehensive Cancer Network. Clinical practice guidelines in oncology—v.1.2002—prostate cancer. Available from URL: www.nccn.org [accessed August 28, 2002].
  • 23
    Royal College of Radiologists COIN (Clinical Oncology Information Network) and British Association of Urological surgeons. Guidelines on the management of prostate cancer. Available from URL: http://www.rcr.ac.uk/prostate.html [accessed October 16, 2001].
  • 24
    American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statements on radiation therapy of prostate cancer: guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. J Clin Oncol. 1999; 17: 1155–1163.
  • 25
    National Health and Medical Research Council. Guide to the development, implementation and evaluation of clinical practice guidelines. Appendix B. Canberra: National Health and Medical Research Council, 1998: 56.
  • 26
    Australian Institute of Health and Welfare (AIHW) and Australasian Association of Cancer Registries (AACR). Cancer in Australia 1998. CAN 12. 2001. Cancer Series No 17. Canberra: AIHW.
  • 27
    Sandock DS, Seftel AD, Resnick MI. A new protocol for the followup of renal cell cancer based on pathological stage. J Urol. 1995; 154: 28–31.
  • 28
    Aref I, Bociek G, Salhani D. Is post-operative radiation for renal cell cancer justified? Radiother Oncol. 1997; 43: 155–157.
  • 29
    Ljungberg B, Landberg G, Alamdari FI. Factors of importance for prediction of survival in patients with metastatic renal cell cancer, treated with or without nephrectomy. Scand J Urol Nephrol. 2000; 34: 246–251.
  • 30
    Slaton JW, Swanson DA, Grossman HB, Dinney CPN. A stage specific approach to tumor surveillance after radical cystectomy for transitional cell cancer of the bladder. J Urol. 1999; 162: 710–714.
  • 31
    Sternberg CN, Yagoda A, Scher HI, et al. Methotrexate, vinblastine, doxorubicin and cisplatin for advanced transitional cell cancer of the urothelium. Cancer. 1989; 64: 2448–2458.
    Direct Link:
  • 32
    Sengelov L, Kamby C, von der Maase H. Pattern of metastases in relation to characteristics of primary tumor and treatment in patients with disseminated urothelial cancer. J Urol. 1996; 155: 111–114.
  • 33
    Koppie TM, Grossfeld GD, Miller D, et al. Patterns of treatment of patients with prostate cancer initially managed with surveillance: results from the CaPSURE database. J Urol. 2000; 164: 81–88.
  • 34
    Markiewicz D, Hanks GE. Therapeutic options in the management of incidental cancer of the prostate. Int J Radiat Oncol Biol Phys. 1991; 20: 153–167.
  • 35
    Bentvelsen FM, Van den Ouden D, Schroder FH. Prostate specific antigen in screening for recurrence following radical prostatectomy for localized prostate cancer. Br J Urol. 1993; 72: 88–91.
    Direct Link:
  • 36
    Zincke H, Bergstrahl EJ, Blute ML, et al. Radical prostatectomy for clinically localized prostate cancer: long-term results of 1143 patients from a single institution. J Clin Oncol. 1994; 12: 2254–2263.
  • 37
    Congdon P. Bayesian statistical modelling. New York: John Wiley & Sons, 2002.
  • 38
    Cancer Statistics Branch, National Cancer Institute. Surveillance, Epidemiology and End Results (SEER) program public-use CD-ROM (1973-1997). Bethesda: National Cancer Institute, 2000.
  • 39
    SA Cancer Registry. Epidemiology of cancer in South Australia (Cancer Series No. 22). Adelaide: South Australian Cancer Registry, 2000.
  • 40
    Moller TR, Brorsson B, Ceberg J, et al. A prospective survey of radiotherapy practice in 2001 in Sweden. Acta Oncol. 2003; 42: 387–410.
  • 41
    Northern and Yorkshire Cancer Registry and Information Service (NYCRIS). Northern and Yorkshire Cancer Networks. A report on incidence and management for the main sites of cancer 1999. Available from URL: http://www.nycris.org.uk/ [accessed November 25, 2003].
  • 42
    Priestman TJ, Dunn J, Brada M, Rampling R, Baker PG. Final results of the Royal College of Radiologists' trial comparing two different radiotherapy schedules in the treatment of cerebral metastases. Clin Oncol (R Coll Radiol). 1996; 8: 308–315.
  • 43
    Kurtz JM, Gelber R, Brady LW, Carella RJ, Cooper JS. The palliation of brain metastases in a favorable patient population: a randomized clinical trial by the radiation therapy oncology group. Int J Radiat Oncol Biol Phys. 1981; 7: 891–895.
  • 44
    Borgelt B, Gelber R, Kramer S, et al. The palliation of brain metastases: final results of the first two studies by the radiation therapy oncology group. Int J Radiat Oncol Biol Phys. 1980; 6: 1–9.
  • 45
    Steenland E, Leer J, Van-Houwelingen H, et al. The effect of a single fraction compared to multiple fractions on painful bone metastases: a global analysis of the Dutch Bone Metastasis Study. Radiother Oncol. 1999; 52: 101–109.
  • 46
    Nielsen OS, Bentzen SM, Sandberg E, et al. Randomised trial of single dose versus fractionated palliative radiotherapy of bone metastases. Radiother Oncol. 1998; 47: 233–240.
  • 47
    Tong D, Gillick L, Hendrickson FR. The palliation of symptomatic osseous metastases. The final results of the study by the Radiation Therapy Oncology Group. Cancer. 1982; 50: 893–899.
    Direct Link:
  • 48
    Duchesne GM. Surgery or radiotherapy for bladder cancer? [letter to the editor]. Clin Oncol (R Coll Radiol). 2002; 14: 519–520.
  • 49
    Campbell SC, Novick AC. Management of local recurrence following radical nephrectomy or partial nephrectomy. Urol Clin North Am. 1994; 21: 593–599.
  • 50
    Ljungberg B, Alamdari FI, Rasmuson T, Roos G. Follow-up guidelines for nonmetastatic renal cell cancer based on the occurrence of metastases after radical nephrectomy. BJU Int. 1999; 84: 405–411.
    Direct Link:
  • 51
    Levy DA, Slaton JW, Swanson DA, Dinney CP. Stage specific guidelines for surveillance after radical nephrectomy for local renal cell cancer. J Urol. 1998; 159: 1163–1167.
  • 52
    Nativ O, Sabo E, Raviv G, et al. The impact of tumor size on clinical outcome in patients with localized renal cell cancer treated by radical nephrectomy. J Urol. 1997; 158: 729–732.
  • 53
    Schouten LJ, Rutten J, Huveneers HA, Twijnstra A. Incidence of brain metastases in a cohort of patients with cancer of the breast, colon, kidney, lung and melanoma. Cancer. 2002; 94: 2698–2705.
    Direct Link:
  • 54
    Harada Y, Nonomura N, Kondo M, et al. Clinical study of brain metastases of renal cell cancer. Eur Urol. 1999; 36: 230–-235.
  • 55
    Mickisch GHJ, Garin A, van Poppel H, et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon-alpha alone in metastatic renal-cell cancer: a randomised trial. Lancet. 2001; 358: 966–970.
  • 56
    Holmang S, Johansson SL. Stage Ta-T1 bladder cancer: the relationship between findings at first followup cystoscopy and subsequent recurrence and progression. J Urol. 2002; 167: 1634–1637.
  • 57
    Freeman JA, Esrig D, Stein JP, et al. Radical cystectomy for high risk patients with superficial bladder cancer in the era of orthotopic urinary reconstruction. Cancer. 1995; 76: 833–839.
    Direct Link:
  • 58
    Herr HW, Schwalb DM, Zhang ZF, et al. Intravesical Bacillus Calmette-Guerin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial. J Clin Oncol. 1995; 13: 1404–1408.
  • 59
    Herr HW, Bochner BH, Dalbagni G, et al. Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer. J Urol. 2002; 167: 1295–1298.
  • 60
    Thomas DJ, Roberts JT, Hall RR, Reading J. Radical transurethral resection and chemotherapy in the treatment of muscle-invasive bladder cancer: a long-term follow-up. BJU Int. 1999; 83: 432–437.
    Direct Link:
  • 61
    Toner GC, Neerhut GJ, Schwarz MA, et al. The management of testicular cancer in Victoria, 1988-1993. Med J Aust. 2001; 174: 328–331.
  • 62
    Weir HK, Marrett LD, Moravan V. Trends in the incidence of testicular germ cell cancer in Ontario by histological subgroup, 1964-1996. Can Med Assoc J. 1999; 160: 201–205.
  • 63
    von der Maase H, Specht L, Jacobsen GK, et al. Surveillance following orchidectomy for stage I seminoma of the testis. Eur J Cancer. 1993; 29A: 1931–1934.
  • 64
    Gospodarowicz M, Sturgeon JFG, Jewett MAS. Early stage and advanced seminoma: role of radiation therapy, surgery and chemotherapy. Semin Oncol. 1998; 25: 160–173.
  • 65
    Duchesne GM, Stenning SP, Aass N, et al. Radiotherapy after chemotherapy for metastatic seminoma—a diminishing role. Eur J Cancer. 1997; 33: 829–835.
  • 66
    International Germ Cell Cancer Collaborative Group. International germ cell consensus classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol. 1997; 15: 594–603.
  • 67
    Warde P, Gospodarowicz M, Panzarella T, et al. Management of stage II seminoma. J Clin Oncol. 1998; 16: 290–294.
  • 68
    Logothetis CJ, Samuels ML, Ogden SL, et al. Cyclophosphamide and sequential cisplatin for advanced seminoma: long-term follow-up in 52 patients. J Urol. 1987; 138: 789–794.
  • 69
    Fossa SD, Droz JP, Stoter G, et al. Cisplatin, vincristine and ifosphamide combination chemotherapy of metastatic seminoma: results of EORTC trial 30874. Br J Cancer. 1995; 71: 619–624.
  • 70
    Pizzocaro G, Salvioni R, Piva L, et al. Cisplatin combination chemotherapy in advanced seminoma. Cancer. 1986; 58: 1625–1629.
    Direct Link:
  • 71
    Wilkinson PM, Read G, Magee B. The treatment of advanced seminoma with chemotherapy and radiotherapy. Br J Cancer. 1988; 57: 100–104.
  • 72
    Schmoll HJ, Harstrick A, Bokemeyer C, et al. Single-agent carboplatinum for advanced seminoma. Cancer. 1993; 72: 237–243.
    Direct Link:
  • 73
    Loehrer PJ, Birch R, Williams SD, et al. Chemotherapy of metastatic seminoma: the Southeastern Cancer Study Group Experience. J Clin Oncol. 1987; 5: 1212–1220.
  • 74
    Kelty P, Frazier H, O'Connell K, Ghosh BC. Germ cell testis cancer: 15-year review. J Surg Oncol. 1996; 62: 30–33.
    Direct Link:
  • 75
    Motzer RJ, Geller NL, Tan CY, et al. Salvage chemotherapy for patients with germ cell tumors. The Memorial Sloan-Kettering cancer center experience (1979-1989). Cancer. 1991; 67: 1305–1310.
    Direct Link:
  • 76
    Howard GCW, Clarke K, Elia MH, et al. A Scottish national audit of current patterns of management for patients with testicular non-seminomatous germ-cell tumours. Br J Cancer. 1995; 72: 1303–1306.
  • 77
    Ozols RF, Ihde DC, Linehan WM, et al. A randomized trial of standard chemotherapy v a high-dose chemotherapy regimen in the treatment of poor prognosis nonseminomatous germ-cell tumors. J Clin Oncol. 1988; 6: 1031–1040.
  • 78
    Harlan LC, Potosky A, Gilliland FD, et al. Factors associated with initial therapy for clinically localized prostate cancer: prostate cancer outcomes study. J Natl Cancer Inst. 2001; 93: 1864–1871.
  • 79
    Zincke H, Oesterling JE, Blute ML, Bergstrahl EJ, Myers RP, Barrett DM. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol. 1994; 152: 1850–1857.
  • 80
    Grossfeld GD, Chang JJ, Broering JM, et al. Impact of positive surgical margins on prostate cancer recurrence and the use of secondary cancer treatment: data from the CaPSURE database. J Urol. 2000; 163: 1171–1177.
  • 81
    Kattan MW, Wheeler TM, Scardino PT. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol. 1999; 17: 1499–1507.
  • 82
    Kupelian PA, Katcher J, Levin HS, Klein EA. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy. Int J Radiat Oncol Biol Phys. 1997; 37: 1043–1052.
  • 83
    Babaian RJ, Troncoso P, Bhadkamkar VA, Johnston DA. Analysis of clinicopathologic factors predicting outcome after radical prostatectomy. Cancer. 2001; 91: 1414–1422.
    Direct Link:
  • 84
    Ohori M, Wheeler TM, Kattan MW, Goto Y, Scardino PT. Prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol. 1995; 154: 1818–1824.
  • 85
    Obek C, Sadek S, Lai S, Civantos F, Rubinowicz D, Soloway MS. Positive surgical margins with radical retropubic prostatectomy: anatomic site-specific pathologic analysis and impact on prognosis. Urology. 1999; 54: 682–688.
  • 86
    Alsikafi NF, Brendler CB. Surgical modifications of radical retropubic prostatectomy to decrease incidence of positive surgical margins. J Urol. 1998; 159: 1281–1285.
  • 87
    Ramos CG, Carvalhal GF, Smith DS, Mager DE, Catalona WJ. Clinical and pathological characteristics, and recurrence rates of stage T1C versus T2A or T2B prostate cancer. J Urol. 1999; 161: 1525–1529.
  • 88
    Epstein JI, Partin AW, Sauvageot J, Walsh PC. Prediction of progression following radical prostatectomy. A multivariate analysis of 721 men with long-term follow-up. Am J Surg Pathol. 1996; 20: 286–292.
  • 89
    Graefen M, Noldus J, Pichlmeier U, et al. Early prostate-specific antigen relapse after radical retropubic prostatectomy: prediction on the basis of preoperative and postoperative tumor characteristics. Eur Urol. 1999; 36: 21–30.
  • 90
    Murphy GP, Mettlin C, Menck H, Winchester DP, Davidson AM. National patterns of prostate cancer treatment by radical prostatectomy: results of a survey by the American College of Surgeons commission on cancer. J Urol. 1994; 152: 1817–1819.
  • 91
    Stamey TA, McNeal JE, Yemoto CM, Sigal BM, Johnstone IM. Biological determinants of cancer progression in men with prostate cancer. JAMA. 1999; 281: 1395–1400.
  • 92
    Paulson DF, Moul JW, Walther PJ. Radical prostatectomy for clinical stage T1-2N0M0 prostatic adenocancer: long-term results. J Urol. 1990; 144: 1180–1184.
  • 93
    Smitt MC, Heltzel M. The results of radical prostatectomy at a community hospital during the prostate specific antigen era. Cancer. 1996; 77: 928–933.
    Direct Link:
  • 94
    Quinn DI, Henshall SM, Haynes A, et al. Prognostic significance of pathologic features in localized prostate cancer treated with radical prostatectomy: implications for staging systems and predictive models. J Clin Oncol. 2001; 19: 3692–3705.
  • 95
    Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999; 281: 1591–1597.
  • 96
    Frazier HA, Robertson JE, Humphrey PA, Paulson DF. Is prostate specific antigen of clinical importance in evaluating outcome after radical prostatectomy? J Urol. 1993; 149: 516-518.
  • 97
    Sarosdy MF, Schellhammer PF, Sharifi R, et al. Comparison of goserelin and leuprolide in combined androgen blockade therapy. Urology. 1998; 52: 82–88.
  • 98
    Adolfsson J, Ronstrom L, Lowhagen T, Carstensen J, Hedlund PO. Deferred treatment of clinically localized low grade prostate cancer: the experience from a prospective series at the Karolinska hospital. J Urol. 1994; 152: 1757–1760.
  • 99
    Epstein JI, Paull G, Eggleston JC, Walsh PC. Prognosis of untreated stage A1 prostatic cancer: a study of 94 cases with extended followup. J Urol. 1986; 136: 837–839.
View Full Article (HTML) Get PDF (298K)